Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy-Reference-Cited by-同舟云学术

Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy

Published:2020-01-01 Issue:1 Volume:9 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Rentsch Cyrill A.¹,Bosshard Piet¹²^ORCID,Mayor Grégoire³,Rieken Malte¹,Püschel Heike¹,Wirth Grégory³,Cathomas Richard⁴,Parzmair Gerald P.⁵,Grode Leander⁵,Eisele Bernd⁵,Sharma Hitt⁶,Gupta Manish⁶,Gairola Sunil⁶^ORCID,Shaligram Umesh⁶,Goldenberger Daniel⁷,Spertini François⁸,Audran Régine⁸^ORCID,Enoiu Milica⁹,Berardi Simona⁹,Hayoz Stefanie⁹^ORCID,Wicki Andreas¹⁰

Affiliation:

1. Department of Urology, University Hospital Basel, University of Basel, Basel, Switzerland

2. Department of Urology, University Hospital Bern, University of Bern, Bern, Switzerland

3. Department of Urology, University Hospital Geneva, University of Geneva, Geneva, Switzerland

4. Department of Oncology, Cantonal Hospital Chur, Chur, Switzerland

5. Vakzine Projekt Management GmbH, Hannover, Germany

6. Serum Institute of India Pvt. Ltd., Pune, India

7. Department of Clinical Bacteriology & Mycology, University Hospital Basel, University of Basel, Basel, Switzerland

8. Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland

9. SAKK Coordinating Center, Bern, Switzerland

10. Department of Oncology, University Hospital Basel, University of Basel, Switzerland

Funder

State Secretary for Education, Research and Innovation

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2020.1748981

Reference23 articles.

1. Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials

2. Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.

3. An Individual Patient Data Meta-Analysis of the Long-Term Outcome of Randomised Studies Comparing Intravesical Mitomycin C versus Bacillus Calmette-Guérin for Non–Muscle-Invasive Bladder Cancer

4. Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bladder Cancer: Immunotherapy and Pelvic Lymph Node Dissection;Vaccines;2024-01-31

2. New Intravesical Agents for BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer;Bladder Cancer;2023-09-25

3. Bacterial Drug Delivery Systems for Cancer Therapy: “Why” and “How”;Pharmaceutics;2023-08-27

4. Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy – protocol of a multicentre, single arm phase 2 trial (SAKK 06/19);BMJ Open;2023-06

5. Efficacy of recombinant Bacillus Calmette-Guérin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model;Investigative and Clinical Urology;2023